Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.48 |
| ▸ | ITGAV | P06756 | 20/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 17/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20487742 | 0.80 | ITGAV (0.52) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL23542465 | 0.80 | ITGAV (0.50) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL20481090 | 0.80 | ITGAV (0.52) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL23542464 | 0.80 | ITGAV (0.50) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL20481336 | 0.79 | ITGAV (0.48) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL20481337 | 0.79 | ITGAV (0.48) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL20481335 | 0.79 | ITGAV (0.48) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL20480993 | 0.78 | ITGAV (0.49) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL7095934 | 0.78 | ITGB3 (0.51) | ITGB3ITGAVITGB5ITGB1ITGA2B | |
| SCHEMBL7098375 | 0.78 | ITGAV (0.50) | ITGB3ITGAVITGB5ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGB3 12/4885ITGAV 3/4885ITGB5 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.